CureVac Reports Unfavorable Covid-19 Vaccine Study Results Amid High Levels of Variants
June 16 2021 - 6:26PM
Dow Jones News
By Josh Beckerman
CureVac NV reported unfavorable results in the second interim
analysis of Covid-19 vaccine candidate CVnCoV, noting an
"unprecedented broad diversity" of virus variants.
CureVac shares were recently down 50% after hours to $47.20.
"In the unprecedented context of at least 13 variants
circulating within the study population subset assessed at this
interim analysis, CVnCoV demonstrated an interim vaccine efficacy
of 47% against COVID-19 disease of any severity and did not meet
prespecified statistical success criteria," CureVac said. The
favorable safety profile of the vaccine was confirmed.
The HERALD study, conducted by CureVac in conjunction with
Bayer, enrolled about 40,000 people in 10 countries in Latin
America and Europe.
In total, 134 Covid-19 cases were assessed in the interim
analysis, with 124 of these sequenced to identify the variant
causing the infection. The outcome confirms that only one case was
attributable to the original SARS-CoV-2 virus, CureVac said.
In March, CureVac said it planned to expand and further specify
the protocols of its CVnCoV trials, saying, "Rapid distribution of
new virus variants in the countries where the study is conducted
supports the need for further analysis specification for the
anticipated case-driven interim analysis."
CureVac and GlaxoSmithKline PLC in February announced a
partnership to develop a vaccine for emerging variants.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 16, 2021 18:11 ET (22:11 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer (TG:BAYN)
Historical Stock Chart
From Sep 2023 to Sep 2024